ATG16L1 and colorectal carcinoma: Moreover, CRC patients with the ATG16L1 T300A genetic variant have a longer life expectancy than the WT counterpart, with higher production of type I IFN via the MAVS pathway, which may help constrain CRC through immune invasion (Grimm et al., 2016).